.png)
SummaryEvery European price list carries list prices. None of them carries what was actually paid. That single sentence explains most of the confusion in cross-country pricing work: the published figure is a regulated or notified price, while the transaction price is reduced by rebates, discounts and clawbacks that are confidential in several markets by design. This article sets out what the two terms mean in practice, which mechanisms create the gap, and how to report a comparison that stays defensible.
List price. The published price at a defined chain position: ex-factory, wholesale, pharmacy purchase or retail. It is either set by the authority, approved by it or notified to it. Every European price file that you can download or licence carries this type of figure.
Net price. What the payer, the pharmacy or the wholesaler actually pays after all reductions. It exists in contracts and invoices, not in public registers.
The distinction is not academic. A hospital buyer negotiating against a published price is negotiating against a ceiling. A market access team comparing two countries at list level is comparing two regulatory outcomes, not two market outcomes.
The strongest available evidence comes from the authorities themselves. EURIPID, the cooperation of national pricing and reimbursement authorities, harmonises four price levels across roughly 26 countries. Net prices in the sense of actually paid prices had not been implemented as of 2022, although the European Parliament had called for them in 2017.
If the shared database of the authorities that set the prices does not carry paid prices, no commercial dataset carries them either. Any vendor claiming otherwise is either selling modelled estimates or a narrow contractual dataset from one market.
A second piece of evidence is structural: in the 30 countries reviewed for our own price work, the wholesale purchase price, meaning what wholesalers actually pay, is published nowhere.
Five mechanisms recur across Europe, and they differ in whether the result is visible at all.
| Mechanism | What it does | Visible in public data |
|---|---|---|
| Statutory manufacturer rebate | A percentage deducted by law from the price the payer bears | The rate is public, the resulting net figure usually is not |
| Rebate contracts and tenders | A payer or sickness fund contracts a discounted price per product | Existence is often public, the amount rarely |
| Managed entry agreements | Price linked to volume, outcome or budget caps | Existence sometimes public, the terms rarely |
| Confidential negotiated amounts | A negotiated price where publication is restricted | Not visible |
| Clawbacks and payback | A retrospective payment from industry to the payer | Sector level, not per product |
In Germany, for example, the statutory manufacturer rebate is anchored in law, so the rate is knowable even where the resulting net price per pack is not. That is the general pattern: rules are public, amounts are not.
Because the alternative is no comparison at all, and because list prices carry real information as long as they are labelled correctly.
The rule is therefore not to avoid list prices. It is to name them.
Germany is unusual in European comparison because the outcome of its central price negotiation becomes part of the published price. After the early benefit assessment, manufacturer and the national association of sickness funds negotiate a reimbursement amount, and that amount then appears in the price data that the market works with.
For cross-country work this has two consequences. It makes Germany one of the few markets where a negotiated figure, rather than a pure list figure, is visible, which is part of why so many national reference formulae read Germany. And it sets a misleading expectation: a team used to German data assumes that negotiated prices are generally visible in Europe, which they are not.
Even in Germany the visible figure is not the whole story. Rebate contracts between individual sickness funds and manufacturers sit underneath it, and their amounts are not public.
Three questions separate a real dataset from a model:
If the answers are vague, the product is a model. A model can still be useful, as long as it is labelled and its assumptions are visible.
Prices are protected, volumes sometimes are not. Lithuania, for example, has published monthly wholesale sales volumes per pack as open data since 2017, under CC BY 4.0. Where such data exists, it supports a weighted comparison, which is usually more informative than an unweighted list price average across products that sell in completely different quantities.
Sometimes an estimate is unavoidable, for example when a business case needs a net assumption. An estimate is acceptable when it is built from named components and labelled as a model. A usable structure has four parts:
What separates this from guesswork is that every step can be audited afterwards. A reader can disagree with your assumption about the negotiated component and still reuse the first two steps.
The opposite practice, applying a single uniform discount percentage across countries, produces a number that looks authoritative and cannot be checked. It also tends to be wrong in a specific direction, because rebate intensity differs strongly between generic and patent protected segments.
Market access and pricing. Use list prices for launch sequencing and reference basket analysis, which are themselves list based. Do not use them to estimate net revenue per market.
Wholesale and procurement. Treat the published pharmacy purchase price as the ceiling of a negotiation. The margin between ceiling and transaction is exactly the space where purchasing performance is measured, and no dataset will show it to you.
Hospital pharmacy. Tender prices are the operative figure and they are typically confidential. Published prices serve as a plausibility check and as a fallback where no tender exists.
List and net prices answer different questions. Europe publishes the first and protects the second, and even the authorities' own shared database had no paid prices as of 2022. A comparison built on list prices is defensible as long as it says so, states its coverage and its date, and does not silently promote a published ceiling into a market fact.
Related reading: European Drug Pricing Database: how cross-border prices work and Pharma pricing Germany: how the system works, plus ex-factory price and external reference pricing in Europe.
pharmazie.com is the consolidated pharmaceutical data platform by DACON Datenbank Consulting GmbH that bundles 25+ specialist databases into a single search, exclusively for healthcare professionals. Price coverage focuses on the DACH region and a number of further EU countries, with more countries following in the coming months.
